Cingulate Inc (CING) Price & Analysis

Compare

390 Followers

CING Stock Chart & Stats

$3.97

-$0.31(-6.60%)

At close: Jan 08 4:00 PM EST

$3.97

-$0.31(-6.60%)

Day’s Range― - ―

52-Week Range$3.20 - $6.01

Previous CloseN/A

Volume136.88K

Average Volume (3M)190.99K

Market Cap

$26.83M

Enterprise Value-$4.70B

Total Cash (Recent Filing)$6.12M

Total Debt (Recent Filing)$4.58M

Price to Earnings (P/E)―

Beta5.64

Next Earnings

Mar 06, 2026

EPS Estimate

-0.63

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.35

Shares Outstanding6,757,070

10 Day Avg. Volume270,731

30 Day Avg. Volume190,985

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)2.52

Price to Sales (P/S)0.00

P/FCF Ratio-1.01

Enterprise Value/Market Cap-175.33

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit8.12K

Enterprise Value/Ebitda218.91

Forecast

1Y Price Target

$12.00

Price Target Upside202.27% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Drug Delivery TechnologyCingulate's Precision Timed Release (PTR) drug delivery technology can deliver once-daily oral therapies that provide all day efficacy while eliminating the need for boosters.

FDA ApprovalCingulate announced that the FDA accepted its NDA application for CTx-1301 for treating Attention Deficit/Hyperactivity Disorder (ADHD).

Market DifferentiationCTx-1301 had previously demonstrated potential best-in-class onset and duration for ADHD, which is a competitive differentiator in light of ongoing stimulant shortages.

Bears Say

Cingulate Inc News

Cingulate Inc Reinstates Shane Schaffer as CEO

An announcement from Cingulate Inc ( ($CING) ) is now available. Cingulate Inc. announced that as of December...

7d ago

CING

Cingulate price target lowered to $16 from $17 at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $16 from $17 and...

1M ago

CING

Cingulate price target lowered to $16 from $17 at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $16 from $17 and...

1M ago

CING

Cingulate Inc.’s Promising Market Position Bolstered by Strategic Partnerships and Innovative ADHD Treatment

Cingulate Inc, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from...

1M ago

CING

CING Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Cingulate, Inc. (CING) is scheduled to report 3rd quarter earnings on 11/17/2025. Regarding Q3 estimates, Wall Street analysts...

1M ago

CING

Cingulate Inc. Reports Q3 2025 Financial Results

Cingulate, Inc. ( ($CING) ) has released its Q3 earnings. Here is a breakdown of the information Cingulate,...

1M ago

CING

Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year

As of September 30, 2025, Cingulate (CING) had approximately $6.1 million in cash and cash equivalents, a $6.1...

1M ago

CING

Cingulate Inc Signs Note Purchase Agreement with Avondale

Cingulate Inc ( ($CING) ) just unveiled an announcement. On November 7, 2025, Cingulate Inc. entered into a...

1M ago

CING

Cingulate names Downey as CCO to lead launch prep for CTx-1301

Cingulate (CING) announced the appointment of Bryan Downey as Chief Commercial Officer, CCO, following the U.S. Food and...

1M ago

CING

Cingulate presents Phase 3 results for CTx-1301, met primary endpoint

Cingulate (CING) announced that the positive Phase 3 results from its pivotal trial of CTx-1301 in pediatric ADHD,...

2M ago

CING

Strategic Advancements and Partnerships Propel Cingulate Inc. Towards Market Success

Maxim Group analyst Naz Rahman reiterated a Buy rating on Cingulate Inc yesterday and set a price target...

2M ago

CING

Cingulate price target raised to $17 from $10 at Roth Capital

Roth Capital raised the firm’s price target on Cingulate (CING) to $17 from $10 and keeps a Buy...

2M ago

CING

Cingulate Inc’s NDA for CTx-1301 Accepted by FDA

Cingulate Inc ( ($CING) ) just unveiled an update. On October 14, 2025, Cingulate Inc. announced that the...

2M ago

CING

Cingulate announces FDA accepted for review the NDA for CTx-1301

Cingulate (CING) announced that the U.S. Food and Drug Administration, FDA, has accepted for review the New Drug...

2M ago

CING

CING FAQ

What was Cingulate Inc’s price range in the past 12 months?

Cingulate Inc lowest stock price was $3.20 and its highest was $6.01 in the past 12 months.

What is Cingulate Inc’s market cap?

Cingulate Inc’s market cap is $26.83M.

When is Cingulate Inc’s upcoming earnings report date?

Cingulate Inc’s upcoming earnings report date is Mar 06, 2026 which is in 74 days.

How were Cingulate Inc’s earnings last quarter?

Cingulate Inc released its earnings results on Nov 13, 2025. The company reported -$1.35 earnings per share for the quarter, missing the consensus estimate of -$0.88 by -$0.47.

Is Cingulate Inc overvalued?

According to Wall Street analysts Cingulate Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cingulate Inc pay dividends?

Cingulate Inc does not currently pay dividends.

What is Cingulate Inc’s EPS estimate?

Cingulate Inc’s EPS estimate is -0.63.

How many shares outstanding does Cingulate Inc have?

Cingulate Inc has 6,757,070 shares outstanding.

What happened to Cingulate Inc’s price movement after its last earnings report?

Cingulate Inc reported an EPS of -$1.35 in its last earnings report, missing expectations of -$0.88. Following the earnings report the stock price went down -12.368%.

Which hedge fund is a major shareholder of Cingulate Inc?

Currently, no hedge funds are holding shares in CING

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cingulate Inc

Cingulate Inc. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative therapies for the treatment of central nervous system disorders. Operating primarily in the healthcare and pharmaceutical sectors, the company is dedicated to addressing unmet medical needs through its portfolio of proprietary drug candidates, with a particular emphasis on attention deficit/hyperactivity disorder (ADHD) and anxiety disorders.

Cingulate Inc (CING) Earnings & Revenues

Historic Earnings Reports

CING Stock 12 Month Forecast

Average Price Target

$12.00

▲(202.27% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","17":"$17","5.75":"$5.75","9.5":"$9.5","13.25":"$13.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.75,9.5,13.25,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.62,4.572307692307692,5.524615384615385,6.476923076923077,7.429230769230768,8.381538461538462,9.333846153846153,10.286153846153844,11.238461538461538,12.19076923076923,13.143076923076922,14.095384615384614,15.047692307692305,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.62,4.264615384615385,4.909230769230769,5.553846153846154,6.1984615384615385,6.843076923076923,7.487692307692308,8.132307692307691,8.776923076923076,9.42153846153846,10.066153846153846,10.71076923076923,11.355384615384615,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.62,3.956923076923077,4.293846153846154,4.630769230769231,4.967692307692308,5.304615384615385,5.641538461538461,5.978461538461539,6.315384615384616,6.6523076923076925,6.989230769230769,7.326153846153846,7.663076923076924,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.85,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.93,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.73,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >